Welcome to our dedicated page for Iqvia Hldgs news (Ticker: IQV), a resource for investors and traders seeking the latest updates and insights on Iqvia Hldgs stock.
IQVIA Holdings Inc. (symbol: IQV) is a prominent player in the healthcare industry, formed from the merger of Quintiles and IMS Health in 2016. The company operates as a global leader in integrated information and technology solutions, driving advancements in healthcare. With a workforce of approximately 50,000 employees across more than 100 countries, IQVIA is dedicated to helping clients improve their clinical, scientific, and commercial outcomes.
Core Services:
- Research and Development (R&D): IQVIA provides outsourced late-stage clinical trials for pharmaceutical, device, and diagnostic firms. This segment focuses on delivering comprehensive research services to advance medical innovations.
- Technology and Analytics: The company offers aggregated information and technology services, catering to pharmaceutical companies, healthcare providers, payers, and policymakers. IQVIA's data and analytics capabilities extend to clinical trials, including virtual trials, ensuring efficient and effective trial outcomes.
- Contract Sales: IQVIA also maintains a small contract sales business, supporting the commercial needs of its clients.
Recent Achievements and Projects:
IQVIA continues to make significant strides in protecting individual patient privacy while leveraging healthcare data to deliver critical real-world disease and treatment insights. The company's commitment to innovation is evident in its ongoing projects and partnerships aimed at enhancing healthcare outcomes globally.
For more information, visit www.quintilesims.com.
IQVIA Holdings (NYSE:IQV) has announced that Ron Bruehlman, executive vice president and chief financial officer, will be presenting at the TD Cowen Annual Health Care Conference. The presentation is scheduled for Tuesday, March 4, 2025, at 11:10 a.m. ET.
Investors and interested parties can access a live audio webcast of the presentation through IQVIA's Investor Relations website at http://ir.iqvia.com. A replay of the webcast will be made available following the presentation on the same day.
IQVIA (NYSE:IQV) has released its 2024 Sustainability Report, highlighting significant achievements across multiple areas. The company, which serves over 10,000 customers in more than 100 countries, reported notable progress in employee development, healthcare access, environmental impact, and technology innovation.
Key highlights include:
- Investment in 88,000 employees worldwide through education and development programs, with over 1,000 employees participating in leadership development annually
- Expansion of clinical trial diversity and geographic reach, including new sites in Africa and Latin America
- Achievement of 27% reduction in scope 1 and 2 greenhouse gas emissions from 2019 baseline
- Implementation of responsible AI initiatives, including the launch of IQVIA AI Assistant and establishment of the Center for Defensible AI
- Recognition as the No. 1 most admired company in Health Care: Pharmacy and Other Services category on Fortune's World's Most Admired Companies list for the fourth consecutive year
IQVIA reported strong Q4 and full-year 2024 results, with Q4 revenue reaching $3,958 million and full-year revenue of $15,405 million. The company's Q4 performance showed a GAAP Net Income of $437 million and Adjusted EBITDA of $996 million. Technology & Analytics Solutions (TAS) revenue grew 9.5% at constant currency to $1,658 million in Q4.
R&D Solutions achieved quarterly bookings exceeding $2.5 billion with a book-to-bill ratio of 1.20x and maintained a strong contracted backlog of $31.1 billion. The company demonstrated robust cash flow performance with full-year Operating Cash Flow of $2,716 million, up 26% year-over-year, and Free Cash Flow of $2,114 million, up 41%.
IQVIA reaffirmed its 2025 guidance, projecting revenue between $15,725-16,125 million, Adjusted EBITDA of $3,765-3,885 million, and Adjusted Diluted EPS of $11.70-12.10.
IQVIA (NYSE:IQV) has been ranked No. 1 in the Health Care: Pharmacy and Other Services category on the 2025 Fortune® World's Most Admired Companies™ list for the fourth consecutive year. This marks the company's eighth consecutive appearance on the prestigious list.
The company secured top positions in four key attributes: innovation, global competitiveness, people management, and use of corporate assets. The recognition was based on Fortune® and Korn Ferry's comprehensive survey of over 3,300 executives, analyzing 650 companies across nine different attributes, including global business effectiveness, talent management, investment value, and environmental responsibility.
IQVIA Chairman and CEO Ari Bousbib attributed this achievement to the company's employees' dedication to advancing their mission of accelerating innovation for a healthier world. The Fortune® World's Most Admired Companies™ list, established in 1997, serves as a definitive assessment of corporate reputations, evaluating companies based on their industry standing and broader business practices.
IQVIA Holdings (NYSE:IQV) has scheduled its fourth-quarter and full-year 2024 financial results announcement for Thursday, February 6, 2025, before market opening. The management team will host a conference call and webcast at 9:00 a.m. Eastern Time on the same day.
The earnings release and financial information will be available on IQVIA's Investor Relations website. Interested parties must register in advance to participate in the conference call, after which they will receive confirmation details including dial-in information and unique access credentials. A webcast replay will be accessible approximately two hours after the event conclusion.
IQVIA (NYSE:IQV) announced a strategic collaboration with NVIDIA to advance AI applications in healthcare and life sciences. The partnership aims to accelerate IQVIA Healthcare-grade AI™, enabling automated workflows across therapeutic lifecycles while maintaining privacy, regulatory compliance, and patient safety standards.
The collaboration combines IQVIA's Connected Intelligence™ with NVIDIA's AI Foundry service to transform life science processes from R&D through commercialization. IQVIA will utilize NVIDIA's technology stack, including NIM microservices, NeMo, and DGX Cloud platform, with support from NVIDIA's research teams.
Initial solutions from this partnership are expected to reach the market within the calendar year. The collaboration will implement NVIDIA AI Blueprint for multi-modal data extraction, making previously inaccessible information available to AI models and agents.
Digital health continues to evolve with 337,000 apps currently available, alongside 360+ software-based digital therapies and 103 digital diagnostics commercially available. Disease-specific apps are expanding beyond mental health and chronic diseases, with 140 prescription digital therapeutics (DTx) approved for home use and 220+ therapies used in clinical settings.
Despite decreased venture funding, digital health solutions are growing in scope, focusing on specific diseases and integrating AI to personalize care. Germany leads in DTx regulation with 56 approved therapies, followed by the US (46) and UK (20). Notable developments include sensor-based digital biomarkers for patient monitoring, FDA-approved digital endpoints, and AI/ML-enabled diagnostic tools, with 801 AI/ML devices approved by FDA as of June 2024.
IQVIA Holdings (NYSE:IQV) has announced that Ron Bruehlman, executive vice president and chief financial officer, will present at the UBS Healthcare Conference in Rancho Palos Verdes, California. The presentation is scheduled for November 13, 2024, at 1:15 p.m. ET. Interested parties can access a live audio webcast of the presentation through the IQVIA Investor Relations website, with a replay available later the same day.
IQVIA reported Q3 2024 results with revenue of $3,896 million, up 4.3% year-over-year. Technology & Analytics Solutions revenue grew 8.6% to $1,554 million, while R&D Solutions revenue increased 1.9% to $2,162 million. The company achieved GAAP Net Income of $285 million and Adjusted EBITDA of $939 million.
R&D Solutions backlog reached $31.1 billion, up 8.0% year-over-year, with a book-to-bill ratio of 1.06x. Operating Cash Flow was $721 million, and Free Cash Flow was $571 million. The company updated its full-year 2024 guidance, projecting revenue between $15,350-15,400 million and Adjusted EBITDA between $3,675-3,700 million.
IQVIA Holdings Inc. (NYSE:IQV) has announced it will release its third-quarter 2024 financial results on Thursday, October 31, 2024, before the market opens. The company will host a conference call and webcast at 9:00 a.m. Eastern Time on the same day to discuss the results. Investors can access the earnings release and financial information on IQVIA's Investor Relations website.
To participate in the conference call, interested parties must register in advance through a provided link. Upon registration, participants will receive confirmation details for joining the call. The webcast can be accessed from the IQVIA Investor Relations website, and a replay will be available approximately two hours after the live event concludes.
FAQ
What is the current stock price of Iqvia Hldgs (IQV)?
What is the market cap of Iqvia Hldgs (IQV)?
What is IQVIA Holdings Inc.?
What services does IQVIA offer?
How many employees does IQVIA have?
What is IQVIA's focus in the research and development segment?
What is the role of IQVIA's technology and analytics segment?
Does IQVIA conduct virtual clinical trials?
What industries does IQVIA serve?
How does IQVIA protect patient privacy?
Where can I find more information about IQVIA?
When was IQVIA formed?
